Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


India’s Ranbaxy Denies Orchid Hostile Takeover Bid

This article was originally published in PharmAsia News

Executive Summary

Responding to a rash of speculation it plans to acquire Orchid Chemicals, Ranbaxy Laboratories denied the firm plans an all-India hostile takeover. Ranbaxy CEO Malvinder Singh issued the denial, but declined to comment on his firm's relationship with Solrex Pharmaceuticals, which recently increased its stake in Orchid to nearly 12 percent. There has been speculation Solrex is part of the Ranbaxy Group and neither firm is considered likely to be willing to buy 12 percent of another company just to be its financial adviser. Singh's statements suggest Ranbaxy plans to negotiate an amicable takeover. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts